Skip to main content
Log in

In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents

  • Published:
Apoptosis Aims and scope Submit manuscript

Abstract

GL331 is a novel podophyllotoxin-derived compound and is more efficacious than its congener VP-16 in killing several types of cancer cells, that has promoted considerable interest in its possibility of clinical use. In this study, we found that the higher cytotoxicity of GL331 in nasopharyngeal carcinoma NPC-TW01 cells was attributed to the elevated ability to induce apoptotic cell death. In addition to evaluation of GL331's single agent activity, the use of GL331 in combination with other established therapeutic agents was also evaluated. We found that GL331-induced cell cycle perturbation occurred upon initial 8-h exposure, and pretreatment of NPC-TW01 cells with GL331 for 8 h significantly interfered with the cytotoxicities of VP-16, cisplatin, 5-fluorouracil and adriamycin. When the schedule of drug administration was reversed, high-toxic concentrations of these agents revealed an antagonistic effect on GL331; however, their low-toxic doses had the additive or even more-than-additive effect on the cytotoxicity induced by GL331 at 0.1 μM or less, but for GL331 concentrations of greater than 1 μM, the effect became less than additive. These data suggest that overlapping mechanisms could be elicited by GL331 and other agents, and additional preclinical studies are needed to determine the optimal dose combination and administration schedule that will enhance, rather than interfere with, the efficacy of GL331 in combination with other anti-cancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whang-Peng J, HuangT-S.Newtrials of GL331, a novel topoisomerase II inhibitor, in treatment of solid tumors. J Intern Med 84.

  2. Huang T-S, Shu C-H, Shih Y-L, et al. J. Protein tyrosine phosphatase activities are involved in apoptotic cancer cell death induced by GL331, a new homolog of etoposide. Cancer Lett 1996; 110: 77–85.

    Google Scholar 

  3. Huang T-S, Lee C-C, Chao Y, et al. A novel podophyllotoxinderived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceut Res 1999; 16: 997–1002.

    Google Scholar 

  4. Kuo M-L, Shen S-C, Yang C-H, Chuang S-E, Cheng A-L, Huang T-S. Bcl-2 prevents topoisomerase II inhibitor GL331–induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity. Oncogene 1998; 17: 2225–2234.

    Google Scholar 

  5. Huang T-S, Yang WK, Whang-Peng J. GL331–induced disruption of cyclin B1/CDC 2 complex and inhibition of CDC 2 kinase activity. Apoptosis 1996; 1: 213–217.

    Google Scholar 

  6. Huang T-S, Shu C-H, Yang WK, Whang-Peng J. Activation of CDC 25 phosphatase and CDC 2 kinase involved in GL331–induced apoptosis. Cancer Res 1997; 57: 2974–2978.

    Google Scholar 

  7. Sullivan DM, Chow K-C, Ross WE. Topoisomerase II mediated mechanisms of drug resistance. In: Kessel D, ed. Resistance to Antineoplastic Drugs. Boca Raton, FL: CRC Press, 1989: 281–292.

    Google Scholar 

  8. Lin C-T, Chan W-Y, Chen W, et al. Characterization of seven newly established nasopharyngeal carcinoma cell lines. Lab Invest 1993; 68: 716–727.

    Google Scholar 

  9. Shu C-H, Yang WK, Huang T-S. Increased cyclin B1/CDC 2 kinase activity and phosphorylation of Bcl-2 associated with paclitaxel-induced apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 1996; 1: 141–146.

    Google Scholar 

  10. Overbeeke R, Steffens-Nakken H, Vermes I, Reutelingsperger C, Haanen C. Early features of apoptosis detected by four different flow cytometry assays. Apoptosis 1998; 3: 115–121.

    Google Scholar 

  11. Huang T-S, Kuo M-L, Shew J-Y, Chou Y-W, Yang WK. Distinct p53–mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNAdamaging agents. Oncogene 1996; 13: 625–632.

    Google Scholar 

  12. Friedland ML. Combination chemotherapy. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkins, 1992: 90–95.

    Google Scholar 

  13. Pratt WB, Ruddon RW, Ensminger WD, Maybaum J. Choice of drugs for cancer chemotherapy. In: The Anticancer Drugs. New York: Oxford University Press, 1994: 235–246.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, TS., Shu, CH., Lee, CC. et al. In vitro evaluation of GL331's cancer cell killing and apoptosis-inducing activity in combination with other chemotherapeutic agents. Apoptosis 5, 79–85 (2000). https://doi.org/10.1023/A:1009693811093

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009693811093

Navigation